SG11201811291QA - Industrial process for the preparation of cariprazine - Google Patents
Industrial process for the preparation of cariprazineInfo
- Publication number
- SG11201811291QA SG11201811291QA SG11201811291QA SG11201811291QA SG11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA SG 11201811291Q A SG11201811291Q A SG 11201811291QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- trans
- cariprazine
- budapest
- cyclohexyl
- Prior art date
Links
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 title abstract 5
- 229960005123 cariprazine Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- KBMWRCPPPDEVSJ-JUAUBFSOSA-N Cl.CCOC(=O)C[C@H]1CC[C@H](N)CC1 Chemical compound Cl.CCOC(=O)C[C@H]1CC[C@H](N)CC1 KBMWRCPPPDEVSJ-JUAUBFSOSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229910000085 borane Inorganic materials 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- -1 dimethylcarbamoyl Chemical class 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) W I PO I PCT omit n OH iolo III 11111111 El ME 10111110 011 (10) International Publication Number WO 2018/007986 Al C07D 295/06 (2006.01) C07C 275/26 (2006.01) Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a (21) International Application Number: patent (Rule 4.17 (ii)) PCT/1B2017/054094 of inventorship (Rule 4.17(iv)) (22) International Filing Date: Published: 07 July 2017 (07.07.2017) with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: P1600420 08 July 2016 (08.07.2016) HU P1700197 09 May 2017 (09.05.2017) HU (71) Applicant: RICHTER GEDEON NYRT. [HU/HU]; Gyomroi fit 19-21., H-1103 Budapest (HU). (72) Inventors: NEU, Jozsef; Hegedus Gyula u. 44/B., H-1133 Budapest (HU). GARADNAY, Sandor; Langliliom u. 3/ B., 1037 Budapest (HU). SZABO, Minas; Hunyadi fit 112., 5830 Battonya (HU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 1-1 (54) Title: INDUSTRIAL PROCESS FOR THE PREPARATION OF CARIPRAZINE (57) : I n the process of the present invention, cariprazine is prepared by converting (trans-4-amino- cyclohexyl)-acetic acid ethyl ester hydrochloride to trans-4-aminocyclohexyl) acetic acid or its hydrochloride by hydrolysis, from the obtained product with N addition of dimethylcarbamoyl derivative as a suitable reagent (trans-4- {[(dimethylamino)carbonyl]aminol cyclohexyl) acetic acid is formed, then the obtained compound is linked to 1-{2,3-dichloropheny1)—piperazine in the presence of carboxylic acid activating cou- pling reagent, and so 1,1-dimethy1-3-[trans-4-(2- oxo-2-(4-(2,3-dichlorophenyl)piperazin-l-yl-ethyl)cyclohexyl] urea is formed, which c)1: 1-1 is converted to cariprazine borane adduct of formula (2) in the presence of reducing agent, and fmally the product itself is eliminated directly or is obtained from its salt by a known method. The invention also relates to a group of intermediate compounds that are formed ei and/or used in the process according to the present invention. (51) International Patent Classification:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1600420 | 2016-07-08 | ||
| HU1700197A HU231173B1 (en) | 2016-07-08 | 2017-05-09 | Industrial procedure for production of cariprazine |
| PCT/IB2017/054094 WO2018007986A1 (en) | 2016-07-08 | 2017-07-07 | Industrial process for the preparation of cariprazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811291QA true SG11201811291QA (en) | 2019-01-30 |
Family
ID=89992438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811291QA SG11201811291QA (en) | 2016-07-08 | 2017-07-07 | Industrial process for the preparation of cariprazine |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP4043446A3 (en) |
| JP (1) | JP7065824B2 (en) |
| CN (1) | CN109476617B (en) |
| AU (1) | AU2017292177B2 (en) |
| BR (1) | BR112018077305A2 (en) |
| CA (1) | CA3030102A1 (en) |
| DK (1) | DK3481811T3 (en) |
| EA (1) | EA036312B1 (en) |
| ES (1) | ES2924995T3 (en) |
| GE (1) | GEP20217217B (en) |
| HR (1) | HRP20221037T1 (en) |
| HU (2) | HU231173B1 (en) |
| IL (1) | IL264074B (en) |
| LT (1) | LT3481811T (en) |
| MX (2) | MX2021012390A (en) |
| PL (1) | PL3481811T3 (en) |
| PT (1) | PT3481811T (en) |
| RS (1) | RS63480B1 (en) |
| SG (1) | SG11201811291QA (en) |
| SI (1) | SI3481811T1 (en) |
| UA (1) | UA123797C2 (en) |
| WO (1) | WO2018007986A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110240548A (en) * | 2018-03-09 | 2019-09-17 | 上虞京新药业有限公司 | A kind of preparation method of Cariliprazine intermediate |
| CN110317182B (en) * | 2018-03-29 | 2021-10-15 | 上虞京新药业有限公司 | Preparation method of cariprazine |
| CN108586389B (en) * | 2018-06-29 | 2020-06-12 | 成都福柯斯医药技术有限公司 | Method for synthesizing Carilazine |
| CN111712486A (en) * | 2018-09-21 | 2020-09-25 | 上海诚妙医药科技有限公司 | Novel crystal form of cariprazine hydrochloride, preparation method and application thereof |
| CN114539185A (en) * | 2020-11-24 | 2022-05-27 | 上海博志研新药物技术有限公司 | Preparation method of cariprazine and intermediate thereof |
| HUP2100108A1 (en) | 2021-03-12 | 2022-09-28 | Richter Gedeon Nyrt | Process for consecutive continuous-flow reductions in the synthesis of medicinally relevant piperazine derivatives using a new device |
| CN115806510B (en) * | 2023-02-03 | 2023-04-21 | 成都福柯斯医药技术有限公司 | Synthesis method of 3-trans-4- (2-hydroxyethyl) cyclohexyl-1, 1-dimethylurea |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010009912A1 (en) | 1995-02-10 | 2001-07-26 | Christos Tsaklakidis | New derivatives of pyridil piperazine or pyridazinyl piperazyl, process for production thereof and medicaments containing these compounds |
| HU227543B1 (en) | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| UY29161A1 (en) | 2004-10-15 | 2006-04-28 | Bayer Pharmaceuticals Corp | NEW HETEROCICLOS |
| HU230067B1 (en) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Novel piperazine salt and preparation method thereof |
| HU229858B1 (en) | 2008-12-17 | 2014-10-28 | Richter Gedeon Nyrt | Process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester hcl |
| US8912197B2 (en) * | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| HU231227B1 (en) * | 2012-11-29 | 2022-03-28 | Richter Gedeon Nyrt. | Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia |
| ITMI20131693A1 (en) | 2013-10-14 | 2015-04-15 | Chemo Res S L | DERIVATIVES OF 1,4-CYCLOHEXYLAMINE AND THEIR PREPARATION |
| CN105218484B (en) * | 2015-09-14 | 2018-02-23 | 安徽省逸欣铭医药科技有限公司 | Tartaric acid Cariliprazine and preparation method thereof and medical usage |
| CN105330616B (en) * | 2015-12-09 | 2017-09-26 | 苏州明锐医药科技有限公司 | The preparation method of Cariliprazine |
-
2017
- 2017-05-09 HU HU1700197A patent/HU231173B1/en unknown
- 2017-07-07 DK DK17739701.5T patent/DK3481811T3/en active
- 2017-07-07 SG SG11201811291QA patent/SG11201811291QA/en unknown
- 2017-07-07 AU AU2017292177A patent/AU2017292177B2/en active Active
- 2017-07-07 CN CN201780042429.9A patent/CN109476617B/en active Active
- 2017-07-07 JP JP2019500444A patent/JP7065824B2/en active Active
- 2017-07-07 EA EA201990097A patent/EA036312B1/en unknown
- 2017-07-07 HU HUE17739701A patent/HUE059285T2/en unknown
- 2017-07-07 CA CA3030102A patent/CA3030102A1/en not_active Abandoned
- 2017-07-07 HR HRP20221037TT patent/HRP20221037T1/en unknown
- 2017-07-07 PT PT177397015T patent/PT3481811T/en unknown
- 2017-07-07 MX MX2021012390A patent/MX2021012390A/en unknown
- 2017-07-07 UA UAA201901278A patent/UA123797C2/en unknown
- 2017-07-07 LT LTEPPCT/IB2017/054094T patent/LT3481811T/en unknown
- 2017-07-07 WO PCT/IB2017/054094 patent/WO2018007986A1/en unknown
- 2017-07-07 ES ES17739701T patent/ES2924995T3/en active Active
- 2017-07-07 EP EP22165881.8A patent/EP4043446A3/en active Pending
- 2017-07-07 EP EP17739701.5A patent/EP3481811B1/en active Active
- 2017-07-07 RS RS20220747A patent/RS63480B1/en unknown
- 2017-07-07 PL PL17739701.5T patent/PL3481811T3/en unknown
- 2017-07-07 GE GEAP201714994A patent/GEP20217217B/en unknown
- 2017-07-07 MX MX2019000330A patent/MX2019000330A/en unknown
- 2017-07-07 SI SI201731213T patent/SI3481811T1/en unknown
- 2017-07-07 BR BR112018077305-0A patent/BR112018077305A2/en unknown
-
2019
- 2019-01-03 IL IL264074A patent/IL264074B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3481811T (en) | 2022-08-23 |
| JP2019527210A (en) | 2019-09-26 |
| GEP20217217B (en) | 2021-02-10 |
| EP3481811B1 (en) | 2022-05-25 |
| LT3481811T (en) | 2022-08-25 |
| SI3481811T1 (en) | 2022-10-28 |
| EA036312B1 (en) | 2020-10-26 |
| JP7065824B2 (en) | 2022-05-12 |
| ES2924995T3 (en) | 2022-10-13 |
| AU2017292177B2 (en) | 2021-07-29 |
| PL3481811T3 (en) | 2022-09-12 |
| WO2018007986A1 (en) | 2018-01-11 |
| CN109476617A (en) | 2019-03-15 |
| CN109476617B (en) | 2023-04-04 |
| HU231173B1 (en) | 2021-06-28 |
| RS63480B1 (en) | 2022-08-31 |
| MX2021012390A (en) | 2022-07-18 |
| HUE059285T2 (en) | 2022-11-28 |
| DK3481811T3 (en) | 2022-09-05 |
| UA123797C2 (en) | 2021-06-02 |
| EP3481811A1 (en) | 2019-05-15 |
| EP4043446A3 (en) | 2023-01-18 |
| IL264074A (en) | 2019-01-31 |
| IL264074B (en) | 2021-10-31 |
| CA3030102A1 (en) | 2018-01-11 |
| EP4043446A2 (en) | 2022-08-17 |
| AU2017292177A1 (en) | 2019-02-07 |
| HUP1700197A2 (en) | 2018-09-28 |
| EA201990097A1 (en) | 2019-06-28 |
| HRP20221037T1 (en) | 2022-11-11 |
| MX2019000330A (en) | 2019-05-20 |
| BR112018077305A2 (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811291QA (en) | Industrial process for the preparation of cariprazine | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201406888QA (en) | Lysin-glutamic acid dipeptide derivatives | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201900904PA (en) | Methods for cross coupling | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900609PA (en) | Method and system for providing buffer solutions | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators |